Arvinas Ownership | Who Owns Arvinas?
Arvinas Ownership Summary
Arvinas is owned by 105.81% institutional investors, 7.21% insiders. Vanguard group is the largest institutional shareholder, holding 9.80% of ARVN shares. BB Biotech AG Ord is the top mutual fund, with 3.46% of its assets in Arvinas shares.
ARVN Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Arvinas | 105.81% | 7.21% | -13.02% |
| Sector | Healthcare Stocks | 57.39% | 9.93% | 32.68% |
| Industry | Biotech Stocks | 68.48% | 9.65% | 21.87% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 7.06M | 9.80% | $135.39M |
| Ecor1 capital | 6.73M | 9.33% | $128.95M |
| Blackrock funding, inc. /de | 6.57M | 9.11% | $125.87M |
| Blackrock | 6.26M | 8.70% | $166.61M |
| Price t rowe associates inc /md/ | 4.10M | 5.69% | $78.66M |
| Pfizer | 3.46M | 4.80% | $66.29M |
| Rtw investments, lp | 3.33M | 4.64% | $63.92M |
| Bellevue group | 2.39M | 3.31% | $45.81M |
| T. rowe price investment management | 2.21M | 3.06% | $42.33M |
| Ubs group | 2.04M | 2.83% | $39.08M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| New leaf venture partners | 1.59M | 40.64% | $30.40M |
| Aquilo capital management | 328.77K | 9.50% | $6.30M |
| Opaleye management | 1.63M | 5.89% | $33.64M |
| Ecor1 capital | 6.73M | 4.88% | $128.95M |
| Nextech invest | 1.41M | 4.38% | $27.00M |
| Exome asset management | 218.70K | 3.15% | $4.19M |
| Pfizer | 3.46M | 2.56% | $66.29M |
| Avidity partners management lp | 1.36M | 2.56% | $26.03M |
| Affinity asset advisors | 630.00K | 1.62% | $12.08M |
| Logos global management lp | 700.00K | 1.57% | $13.42M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Pfizer | 3.46M | 2.56% | 3.46M |
| T. rowe price investment management | 2.21M | 0.03% | 2.21M |
| Ubs group | 2.04M | 0.01% | 1.57M |
| Norges bank | 1.24M | 0.00% | 1.24M |
| Blackrock | 6.26M | 0.00% | 764.55K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Paradigm biocapital advisors lp | - | - | -2.34M |
| Fmr | 1.56M | 0.00% | -1.32M |
| Braidwell lp | - | - | -1.28M |
| Commodore capital lp | - | - | -1.20M |
| Adage capital partners gp | - | - | -630.00K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Pfizer | 3.46M | 2.56% | 3.46M | $66.29M |
| T. rowe price investment management | 2.21M | 0.03% | 2.21M | $42.33M |
| Norges bank | 1.24M | 0.00% | 1.24M | $23.84M |
| Caption management | 206.91K | 0.04% | 206.91K | $3.97M |
| Twinbeech capital lp | 164.11K | 0.05% | 164.11K | $3.15M |
Sold Out
| Holder | Change |
|---|---|
| Capital performance advisors llp | -6.00 |
| Clearstead advisors | -13.00 |
| Avion wealth | -33.00 |
| Bessemer group | -40.00 |
| Abich financial wealth management | -43.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2024 | 208 | -4.59% | 76,287,067 | 7.32% | 105 | 1.09% | 111 | 9.90% | 51 | -22.73% |
| Sep 30, 2024 | 217 | 3.33% | 71,015,986 | 0.13% | 98 | 1.01% | 99 | -18.18% | 67 | 26.42% |
| Jun 30, 2024 | 210 | -7.89% | 70,926,259 | 4.97% | 98 | 1.11% | 121 | - | 53 | -18.46% |
| Mar 31, 2024 | 228 | 3.64% | 67,567,208 | 4.28% | 94 | 0.84% | 121 | -20.39% | 65 | 51.16% |
| Dec 31, 2023 | 220 | 41.03% | 64,796,958 | 34.08% | 106 | 1.33% | 152 | 85.37% | 43 | -10.42% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BB Biotech AG Ord | 2.38M | 3.46% | - |
| US Small-Cap Growth II Equity Comp | 2.02M | 2.93% | - |
| T. Rowe Price New Horizons | 2.02M | 2.93% | - |
| Vanguard Total Stock Mkt Idx Inv | 1.94M | 2.82% | - |
| Vanguard US Total Market Shares ETF | 1.93M | 2.81% | 2.43K |
| iShares Russell 2000 ETF | 1.70M | 2.47% | -14.74K |
| Vanguard Small Cap Index | 1.58M | 2.30% | 1.28K |
| Vanguard Explorer Inv | 1.20M | 1.75% | 271.21K |
| T. Rowe Price Integrated US SmCapGrEq | 973.87K | 1.42% | 610.44K |
| Vanguard Institutional Extnd Mkt Idx Tr | 964.91K | 1.40% | 1.66K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 18, 2025 | Berkowitz Noah | Chief Medical Officer | Sell | $74.37K |
| Feb 24, 2025 | Loomis David K | Chief Accounting Officer | Sell | $20.33K |
| Feb 24, 2025 | Cacace Angela M | Chief Scientific Officer | Sell | $51.27K |
| Feb 24, 2025 | Cacace Angela M | Chief Scientific Officer | Sell | $18.97K |
| Feb 24, 2025 | Taylor Ian | President, R&D | Sell | $123.21K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q1 | - | 8 |
| 2024 Q4 | - | 1 |
| 2024 Q2 | - | - |
| 2024 Q1 | - | 4 |
| 2023 Q3 | - | 1 |
ARVN Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools